-
1
-
-
33646245937
-
Adaptive designs in clinical drug development– an executive summary of the phrma working group
-
Gallo P, Chuang-Stein C, Dragalin V, et al. Adaptive designs in clinical drug development– An executive summary of the PhRMA working group. J Biopharm Stat 2006; 16: 275–83.
-
(2006)
J Biopharm Stat
, vol.16
, pp. 275-283
-
-
Gallo, P.1
Chuang-Stein, C.2
Dragalin, V.3
-
2
-
-
36249017451
-
Adaptive designs in clinical drug development: Opportunities, challenges, and scope rel ections following phrma’s november 2006 workshop
-
Krams M, Burman CF, Dragalin V, et al. Adaptive designs in clinical drug development: Opportunities, challenges, and scope rel ections following PhRMA’s November 2006 workshop. J Biopharm Stat 2007; 17: 957–64.
-
(2007)
J Biopharm Stat
, vol.17
, pp. 957-964
-
-
Krams, M.1
Burman, C.F.2
Dragalin, V.3
-
3
-
-
44949171503
-
Adaptive design methods in clinical trials–a review
-
Chow SC and Chang M. Adaptive design methods in clinical trials–A review. Orphanet JRare Dis 2008; 3: 11.
-
(2008)
Orphanet J
, vol.3
-
-
Chow, S.C.1
Chang, M.2
-
4
-
-
46349091495
-
Adaptive clinical trials: Progress and challenges
-
Coffey CS and Kairalla JA. Adaptive clinical trials: Progress and challenges. DrugsRD 2008; 9: 229–42.
-
(2008)
Drugs
, vol.9
, pp. 229-242
-
-
Coffey, C.S.1
Kairalla, J.A.2
-
5
-
-
66249141976
-
Adaptivity in drug discovery and development
-
Bretz F, Branson M, Burmann CF, et al. Adaptivity in drug discovery and development. Drug Dev Res 2009; 70: 169–90.
-
(2009)
Drug Dev Res
, vol.70
, pp. 169-190
-
-
Bretz, F.1
Branson, M.2
Burmann, C.F.3
-
6
-
-
65649093620
-
Adaptive designs for confirmatory clinical trials
-
Bretz F, Koenig F, Brannath W, et al. Adaptive designs for confirmatory clinical trials. Stat Med 2009; 28: 1181–1217.
-
(2009)
Stat Med
, vol.28
, pp. 1181-1217
-
-
Bretz, F.1
Koenig, F.2
Brannath, W.3
-
9
-
-
46349093564
-
A regulatory view on adaptive/flexible clinical trial design
-
Hung HMJ, O’Neill RT, Wang SJ, et al. A regulatory view on adaptive/flexible clinical trial design. Biometrical J 2006; 3: 1–9.
-
(2006)
Biometrical
, vol.3
, pp. 1-9
-
-
Hung, H.1
O’Neill, R.T.2
Wang, S.J.3
-
11
-
-
33644597596
-
The continual reassessment method for dose-finding studies: A tutorial
-
Garrett-Moyer E. The continual reassessment method for dose-finding studies: A tutorial. Clin Trials 2006; 3: 57–71.
-
(2006)
Clin Trials
, vol.3
, pp. 57-71
-
-
Garrett-Moyer, E.1
-
12
-
-
54349105104
-
Dose finding– a challenge in statistics
-
Bretz F, Hsu J, Pinheiro J, et al. Dose finding– A challenge in statistics. Biometrical J2008; 50: 480–504.
-
(2008)
Biometrical J
, vol.50
, pp. 480-504
-
-
Bretz, F.1
Hsu, J.2
Pinheiro, J.3
-
14
-
-
36248961734
-
Innovative approaches for designing and analyzing adaptive doseranging trials
-
Bornkamp B, Bretz F, Dmitrienko A, et al. Innovative approaches for designing and analyzing adaptive doseranging trials. J Biopharm Stat 2007; 17: 965–95.
-
(2007)
J Biopharm Stat
, vol.17
, pp. 965-995
-
-
Bornkamp, B.1
Bretz, F.2
Dmitrienko, A.3
-
16
-
-
0032989951
-
Randomized play-the-winner clinical.Trials: Review and recommendations
-
Rosenberger WF. Randomized play-the-winner clinical.trials: Review and recommendations.Control Clin Trials 1999; 20: 328–42.
-
(1999)
Control Clin Trials
, vol.20
, pp. 328-342
-
-
Rosenberger, W.F.1
-
17
-
-
0343088226
-
Bandit strategies for ethical sequential allocation. Control clin
-
Hardwick JP and Stout QF. Bandit strategies for ethical sequential allocation. Control ClinTrials 1991; 23: 421–24.
-
(1991)
Trials
, vol.23
, pp. 421-424
-
-
Hardwick, J.P.1
Stout, Q.F.2
-
18
-
-
77249096450
-
The use of minimization in clinical trials
-
Taves DR. The use of minimization in clinical trials. Contemp Clin Trials2010; 31: 180–84.
-
(2010)
Contemp Clin Trials
, vol.31
, pp. 180-184
-
-
Taves, D.R.1
-
19
-
-
0028619850
-
Evaluation of experiments with adaptive interim analyses
-
Bauer P and Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029–41.
-
(1994)
Biometrics
, vol.50
, pp. 1029-1041
-
-
Bauer, P.1
Kohne, K.2
-
20
-
-
0029589385
-
Designed extension of studies based on conditional power
-
Proschan MA and Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995; 51: 1315–24.
-
(1995)
Biometrics
, vol.51
, pp. 1315-1324
-
-
Proschan, M.A.1
Hunsberger, S.A.2
-
21
-
-
0032732411
-
Adaptive sample size calculations in group sequential trials
-
Lehmacher W and Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55: 1286–90.
-
(1999)
Biometrics
, vol.55
, pp. 1286-1290
-
-
Lehmacher, W.1
Wassmer, G.2
-
22
-
-
0032886394
-
Modifications of sample size in group sequential clinical trials
-
Cui L, Hung HMJ and Wang S. Modifications of sample size in group sequential clinical trials. Biometrics1999; 55: 853–57.
-
(1999)
Biometrics
, vol.55
, pp. 853-857
-
-
Cui, L.1
Hung, H.2
Wang, S.3
-
23
-
-
0034876356
-
Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and classical group sequential approaches
-
Muller HH and Schafer H. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and classical group sequential approaches. Biometrics 2001; 57: 886–91.
-
(2001)
Biometrics
, vol.57
, pp. 886-891
-
-
Muller, H.H.1
Schafer, H.2
-
24
-
-
33748576736
-
Adaptive, group sequential, and decision theoretic approaches to sample size determination
-
Mehta CR and Patel NR. Adaptive, group sequential, and decision theoretic approaches to sample size determination. Stat Med 2006; 25: 3250–69.
-
(2006)
Stat Med
, vol.25
, pp. 3250-3269
-
-
Mehta, C.R.1
Patel, N.R.2
-
25
-
-
1842826262
-
On the inefficiency of the adaptive design for monitoring clinical trials
-
Tsiatis AA and Mehta C. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90: 367–78.
-
(2003)
Biometrika
, vol.90
, pp. 367-378
-
-
Tsiatis, A.A.1
Mehta, C.2
-
26
-
-
33644770078
-
Efficient group sequential designs when there are several eff ect sizes under consideration
-
Jennison C and Turnbull BW. Efficient group sequential designs when there are several eff ect sizes under consideration. Stat Med 2006; 25: 917–32.
-
(2006)
Stat Med
, vol.25
, pp. 917-932
-
-
Jennison, C.1
Turnbull, B.W.2
-
27
-
-
0024994537
-
The role of internal pilot studies in increasing the efficiency of clinical trials
-
Wittes J and Brittain E.The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med 1990; 9: 65–72.
-
(1990)
Stat Med
, vol.9
, pp. 65-72
-
-
Wittes, J.1
Brittain, E.2
-
28
-
-
22044443101
-
Two-stage sample size re-estimation based on a nuisance parameter: A review
-
Proschan MA. Two-stage sample size re-estimation based on a nuisance parameter: A review. J Biopharm Stat 2005; 15: 559–74.
-
(2005)
J Biopharm Stat
, vol.15
, pp. 559-574
-
-
Proschan, M.A.1
-
29
-
-
33748550685
-
Sample size recalculation in internal pilot study designs: A review
-
Friede T and Kieser M. Sample size recalculation in internal pilot study designs: A review. Biometrical J 2006; 48: 537–55.
-
(2006)
Biometrical J
, vol.48
, pp. 537-555
-
-
Friede, T.1
Kieser, M.2
-
30
-
-
66349091397
-
Sample size re-estimation in clinical trials
-
Proschan MA. Sample size re-estimation in clinical trials. Biometrical J 2009; 51: 348–57.
-
(2009)
Biometrical J
, vol.51
, pp. 348-357
-
-
Proschan, M.A.1
-
31
-
-
70249116820
-
Phase ii trial of coq10 for als find insuffi cient evidence to justify phase iii
-
Kaufman P, Thompson JLP, Levy G, et al. Phase II trial of CoQ10 for ALS find insuffi cient evidence to justify phase III. Ann Neurol 2009; 66: 235–44.
-
(2009)
Ann Neurol
, vol.66
, pp. 235-244
-
-
Kaufman, P.1
Thompson, J.2
Levy, G.3
-
33
-
-
0242694372
-
Acute stroke therapy by inhibition of neutrophils (Astin): An adaptive dose-response study of uk-279,276 in acute ischemic stroke
-
Krams M, Lees KR, Hacke W, et al. Acute stroke therapy by inhibition of neutrophils (ASTIN): An adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34: 2543–48.
-
(2003)
Stroke
, vol.34
, pp. 2543-2548
-
-
Krams, M.1
Lees, K.R.2
Hacke, W.3
-
34
-
-
42249087655
-
Randomized controlled trial of an oral cgrp receptor antagonist, mk-0974, in acute treatment of migraine
-
Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70: 1304–12.
-
(2008)
Neurology
, vol.70
, pp. 1304-1312
-
-
Ho, T.W.1
Mannix, L.K.2
Fan, X.3
-
35
-
-
52449120660
-
Practical model-based dose finding in early-phase clinical trials: Optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children
-
Whelan HT, Cook JD, Amlie-Lefond CM, et al. Practical model-based dose finding in early-phase clinical trials: Optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children. Stroke 2008; 39: 2627–36.
-
(2008)
Stroke
, vol.39
, pp. 2627-2636
-
-
Whelan, H.T.1
Cook, J.D.2
Amlie-Lefond, C.M.3
-
36
-
-
67650492245
-
High-dose lovastatin for acute ischemic stroke: Results of the phase i dose escalation neuroprotection with statin therapy for acute recovery trial (neustart)
-
Elkind MSV, Sacco RL, MacArthur RB, et al. High-dose lovastatin for acute ischemic stroke: Results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis 2009; 28: 266–275.
-
(2009)
Cerebrovasc
, vol.28
, pp. 266-275
-
-
Elkind, M.1
Sacco, R.L.2
MacArthur, R.B.3
-
37
-
-
77950251479
-
Phase iib/iii trial of tenecteplase in acute ischemic stroke: Results of a prematurely terminated randomized clinical trial
-
Haley EC, Thompson JLP, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: Results of a prematurely terminated randomized clinical trial. Stroke 2010; 41: 707–711.
-
(2010)
Stroke
, vol.41
, pp. 707-711
-
-
Haley, E.C.1
Thompson, J.2
Grotta, J.C.3
-
38
-
-
1542346238
-
Calcitonin generelated peptide receptor antagonist bibn 4096 bs for the acute treatment of migraine
-
Olesen J, Diener H, Husstedt IW, et al. Calcitonin generelated peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New Engl J Med 2004; 350: 1104–10.
-
(2004)
New Engl J Med
, vol.350
, pp. 1104-1110
-
-
Olesen, J.1
Diener, H.2
Husstedt, I.W.3
-
39
-
-
33750893179
-
Implementing adaptive designs: Logistical and operational considerations
-
Quinlan JA and Krams M. Implementing adaptive designs: Logistical and operational considerations. Drug Information Journal2006; 40: 437–444.
-
(2006)
Drug Information Journal
, vol.40
, pp. 437-444
-
-
Quinlan, J.A.1
Krams, M.2
-
40
-
-
77953666447
-
Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development
-
Quinlan J, Gaydos B, Maca J, et al. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trials 2010; 7: 167–73.
-
(2010)
Clin Trials
, vol.7
, pp. 167-173
-
-
Quinlan, J.1
Gaydos, B.2
Maca, J.3
-
41
-
-
33845891920
-
The design of simulation studies in medical statistics
-
Burton A, Altman DG, Royston P, et al. The design of simulation studies in medical statistics. Stat Med 2006; 25: 4279–92.
-
(2006)
Stat Med
, vol.25
, pp. 4279-4292
-
-
Burton, A.1
Altman, D.G.2
Royston, P.3
-
42
-
-
70350139975
-
Good practices for adaptive clinical trials in pharmaceutical product development
-
Gaydos B, Anderson KM, Berry D, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J 2009; 43: 539–56.
-
(2009)
Drug Inf J
, vol.43
, pp. 539-556
-
-
Gaydos, B.1
Erson, K.M.2
Berry, D.3
|